^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    cafelkibart (LM-108)

    i
    Associations

    News

    Trials
    Company:
    LaNova Medicines Limited
    Drug class:
    CCR8 inhibitor
    Related drugs:
    Associations

    News

    Trials
    17d
    A Study of LM-108 in Combination With Toripalimab in Subjects With Advanced Solid Tumours (clinicaltrials.gov)
    P2, N=84, Not yet recruiting, LaNova Medicines Limited
    New P2 trial • Mismatch repair • IO biomarker
    |
    Loqtorzi (toripalimab-tpzi) • cafelkibart (LM-108)
    6ms
    Study of LM-108 as a Single Agent or in Combination With Anti-PD-1 Antibody in Subjects With Advanced Solid Tumours (clinicaltrials.gov)
    P1/2, N=60, Recruiting, LaNova Australia Pty Limited | Trial completion date: Jun 2024 --> Dec 2024 | Trial primary completion date: Mar 2024 --> Dec 2024
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    cafelkibart (LM-108)
    6ms
    Study of LM-108 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours (clinicaltrials.gov)
    P1/2, N=392, Enrolling by invitation, LaNova Medicines Limited | Recruiting --> Enrolling by invitation
    Enrollment status • Combination therapy • Metastases
    |
    Loqtorzi (toripalimab-tpzi) • cafelkibart (LM-108)
    over1year
    Study of LM-108 as a Single Agent or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumours (clinicaltrials.gov)
    P1/2, N=24, Terminated, LaNova Medicines Limited | N=54 --> 24 | Trial completion date: Dec 2023 --> Aug 2023 | Recruiting --> Terminated | Trial primary completion date: Nov 2023 --> Aug 2023; Completed primary objective.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • cafelkibart (LM-108)
    over1year
    Study of LM-108 as a Single Agent or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumours (clinicaltrials.gov)
    P1/2, N=54, Recruiting, LaNova Medicines Limited | Trial completion date: Sep 2024 --> Dec 2023 | Trial primary completion date: Jul 2024 --> Nov 2023
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • cafelkibart (LM-108)
    3years
    Effective depletion of tumor-infiltrating Tregs by a novel anti-CCR8 antibody (LM-108): Addressing resistance associated with immune checkpoint inhibitors (AACR 2022)
    To conclude, LM-108 is a novel Fc-optimized CCR8 antibody that selectively depletes tumor infiltrating Tregs thereby improving anti-tumor immune response either as monotherapy or combination therapy. Thus, LM-108 can be a promising therapeutic approach to overcome ICI resistance in cancer patients.
    Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CCR4 (C-C Motif Chemokine Receptor 4) • FOXP3 (Forkhead Box P3) • CCR8 (C-C Motif Chemokine Receptor 8)
    |
    CCR8 expression • FOXP3 expression
    |
    cafelkibart (LM-108)